PMN
ProMIS Neurosciences Inc.Key Statistics
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is an innovative biotechnology firm dedicated to developing groundbreaking therapeutic solutions for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Leveraging its proprietary protein engineering platform, the company excels in identifying and targeting misfolded proteins linked to these conditions, positioning its drug candidates to offer enhanced safety and efficacy. With a robust pipeline at various stages of development, ProMIS is strategically positioned to advance critical neurotherapeutic options that address significant unmet medical needs in the biopharmaceutical landscape, making it an appealing prospect for institutional investors seeking growth in the healthcare sector.
Fundamentals
| Revenue (TTM) | 7,560 |
| Gross Profit (TTM) | $-33.38M |
| EBITDA | $-13.31M |
| Operating Margin | 0.00% |
| Return on Equity | -115.70% |
| Return on Assets | -63.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.77 |
| Price-to-Book | 1.62 |
| Price-to-Sales (TTM) | 4016.22 |
| EV/Revenue | 4004.98 |
| EV/EBITDA | -1.74 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.97M |
| Float | $4.60M |
| % Insiders | 11.87% |
| % Institutions | 74.37% |
Historical Volatility
Volatility is currently contracting